2020+ Milestones Emerge

As TOMI and SteraMist combatted the SARS-CoV-2 Coronavirus, SteraMist was registered with the Centers for Disease Control in China, the development of SteraBot was announced, the Commercial division was added to TOMI`s operations, record-breaking revenue was achieved, and the TOMI brand achieved widespread recognition and continues to pursue success.

2019: Expanded Product Line

iHP Plasma Decontamination Chamber was designed and implemented and the SteraMistTotal Disinfection Cart was made available to Healthcare customers. iHP Corporate Service completes their highest-grossing job, and registration from the Minister of Health of Israel and distribution rights were given to Israel-based CleanBit.

2018: TOMI Continues to Expand

In the effort to expand its U.S. Operation Headquarters, TOMI took ownership of its new office containing multiple individual offices and cubicles, two conference rooms, a large warehouse, training room, a quality control room, and a qualification laboratory in Frederick, MD. Installed TOMI`s largest TOMI Custom Engineered System to date at Pfizer Missouri.

2017: Focus on Intellectual Property Rights

TOMI was awarded rights to the iHP registered trademark. BIT label approved to be distributed through its SteraMist product line in Canada. Additional trademark registrations were accepted in multiple countries including Hong Kong, Singapore, and Taiwan. Applications of multiple utility and design patents were submitted, all of which have been published.

EPA label further expanded to include Norovirus and Salmonella. Divisions of TOMI emerged: Hospital-Healthcare, Life Sciences, TOMI Service Network, and Food Safety.

2016: First Custom System Implementation

TOMI expanded its EPA registration, amending to add C. diff spores, allowing access to large U.S. healthcare markets. Engineered and installed the very first Custom Engineered System (CES) at the Dana Farber Cancer Institute at Harvard and England-based ITH Pharma.

2015: EPA Registrations

The EPA registered SteraMist as the only equipment and solution combination for Hospital-Healthcare disinfection and general/multiple-use disinfection (EPA Reg. #90150-2). Registered with the U.S. FDA as a disinfectant medical device (Reg. #3012117386).

2014: Prototype Development

TOMI evaluates the various purchased prototypes and commercializes the manufacturing of its BIT platform products for rapid deployment throughout a variety of global spaces and verticals. TSN is launched.

2013: Purchasing the BIT Platform and All BIT Assets

After approximately two years of negotiations, TOMI purchased all assets of the BIT platform from L-3 Technologies (Formerly known as L-3 Communications Holdings).

Pfizer iHP CES Vaccine - Video